Know Cancer

forgot password

A Phase II Trial of TBL 12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma

Phase 2
18 Years
Open (Enrolling)
Multiple Myeloma

Thank you

Trial Information

A Phase II Trial of TBL 12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma

Multiple myeloma is a cancer that evolves from a state known as Monoclonal Gammopathy of
Undetermined Significance (MGUS), defined by parameters of M spike and bone marrow. After
evolution to myeloma, patients may be asymptomatic, that is, without any endorgan disease of
hypercalcemia, renal insufficiency, anemia or bone lesions. In asymptomatic myeloma (ASxM),
there is no standard therapy. Thalidomide has been tried in patients with ASxM but with
significant toxicity. The patients with ASxM are evaluable in terms of paraprotein
measurements. TBL12 sea cucumber extract has been shown to have a number of antitumor
properties preclinically, including antiangiogenesis and direct tumor cytotoxicity. TBL12
has been used by a number of patients as a food supplement without any toxicity detected.
We thus propose to determine the clinical activity of this agent in patients with ASxM.
Patients will be given TBL12 at the dose of 2 units of 20 mL each twice per day daily for
one year and the effects on the paraprotein noted. Clinical effects seen will be correlated
with any in vitro changes in angiogenesis in patient bone marrow samples. The results of
this trial may form the basis for the use of this nontoxic agent in patients with the
prodrome of or with other early cancers.

Inclusion Criteria:

- Diagnosis of multiple myeloma

- Measurable disease

- For non-secretors, measurable protein by Freelite or plasmacytoma

- Asymptomatic disease

Exclusion Criteria:

- POEMS syndrome

- Plasma cell leukemia

- Receiving steroids greater than the equivalent of 10 mg prednisone

- Infection not controlled by antibiotics

- HIV infection

- Known active hepatitis B or C

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Time to progression to symptomatic disease (CRAB symptoms)

Outcome Description:

To determine the response rate and time to progression of asymptomatic multiple myeloma patients receiving TBL 12.

Safety Issue:


Principal Investigator

Sundar Jagannath, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mount Sinai School of Medicine


United States: Food and Drug Administration

Study ID:

TBL 12



Start Date:

September 2008

Completion Date:

April 2013

Related Keywords:

  • Multiple Myeloma
  • Asymptomatic
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



Mount Sinai Medical CenterNew York, New York  10029